Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for FB102 in Graft-versus-host disease . The expected timing is based on the latest available company guidance and may change.
5/13/24 SAD study complete; MAD dosing ongoing. 11/25/24- R&D day on December 3, 2024 featuring the development of the drug. 3/31/25- Topline results in Q2 2025. 8/14/25- No recent Q2'25 report update. 11/14/25:- PR No update. 03/31/26:- PR No update. 05/11/26:- PR No update.
Verification
Confirm timing and program details against the company announcement or filing.